Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis

PHASE3CompletedINTERVENTIONAL

Enrollment

105

Participants

Timeline

Start Date

February 5, 2021

Primary Completion Date

October 18, 2023

Study Completion Date

October 18, 2023

Conditions

Myelofibrosis

Interventions

DRUG

Jaktinib

Jaktinib Hydrochloride Tablets administered orally twice daily

DRUG

Placebo to match Hydroxycarbamide

Placebo to match Hydroxycarbamide Tablets administered orally twice daily

DRUG

Hydroxycarbamide Tablets

Hydroxycarbamide Tablets administered orally twice daily

DRUG

Placebo to match Jaktinib

Placebo to match Jaktinib Tablets administered orally twice daily

Trial Locations (1)

The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou

All Listed Sponsors

lead

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

INDUSTRY

NCT04617028 - Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis | Biotech Hunter | Biotech Hunter